PDF(Pubmed)
Abstract：
UNASSIGNED: There is a lack of published information outlining the use of biologics in National Football League (NFL) athletes and limited data to guide biologic treatment strategies.
UNASSIGNED: To develop a consensus on the use of biologics among NFL team physicians.
UNASSIGNED: Consensus statement.
UNASSIGNED: A working group of 6 experts convened a consensus process involving NFL team physicians using validated Delphi methodology. Physicians from 32 NFL teams as well as NFL London were invited to take part. This iterative process was used to define statements on the use of biologics in NFL athletes. A recent scoping review exploring biologics in professional athletes was used to inform the first of 3 rounds of surveys, with statements considered under 7 headings: biologics in general, challenges of treating NFL athletes, terminology/nomenclature, autologous blood products, cell-based therapies, guidance for NFL team physicians, and biologic research in the NFL. In addition to rating agreement, experts were encouraged to propose further items or modifications. Predefined criteria were used to refine item lists after each survey. For a consensus within the final round, defined a priori, items were included in the final information set if a minimum of 75% of respondents agreed and fewer than 10% disagreed.
UNASSIGNED: Physicians from 26 NFL teams and NFL London responded to the initial invitation to participate in the Delphi process; 88.9% of participating team physicians completed the round 1 survey, with response rates of 87.5% in round 2 and 95.2% in round 3. After 3 rounds, 47 statements reached a consensus. A consensus was achieved that platelet-rich plasma has a positive impact on patellar tendinopathy and on symptoms in early osteoarthritis but not for other indications. NFL team physicians agreed that while cell therapies have the potential to improve symptoms, the misrepresentation of uncharacterized preparations as \"stem cells\" has contributed to the widespread use of unproven therapies.
UNASSIGNED: This study established an expert consensus on 47 statements relating to the use of biologics in NFL athletes. In addition to providing clinical guidance for the use of biologics in NFL athletes, this study identified key areas for future focus including the development of athlete education materials.
UNASSIGNED: To develop a consensus on the use of biologics among NFL team physicians.
UNASSIGNED: Consensus statement.
UNASSIGNED: A working group of 6 experts convened a consensus process involving NFL team physicians using validated Delphi methodology. Physicians from 32 NFL teams as well as NFL London were invited to take part. This iterative process was used to define statements on the use of biologics in NFL athletes. A recent scoping review exploring biologics in professional athletes was used to inform the first of 3 rounds of surveys, with statements considered under 7 headings: biologics in general, challenges of treating NFL athletes, terminology/nomenclature, autologous blood products, cell-based therapies, guidance for NFL team physicians, and biologic research in the NFL. In addition to rating agreement, experts were encouraged to propose further items or modifications. Predefined criteria were used to refine item lists after each survey. For a consensus within the final round, defined a priori, items were included in the final information set if a minimum of 75% of respondents agreed and fewer than 10% disagreed.
UNASSIGNED: Physicians from 26 NFL teams and NFL London responded to the initial invitation to participate in the Delphi process; 88.9% of participating team physicians completed the round 1 survey, with response rates of 87.5% in round 2 and 95.2% in round 3. After 3 rounds, 47 statements reached a consensus. A consensus was achieved that platelet-rich plasma has a positive impact on patellar tendinopathy and on symptoms in early osteoarthritis but not for other indications. NFL team physicians agreed that while cell therapies have the potential to improve symptoms, the misrepresentation of uncharacterized preparations as \"stem cells\" has contributed to the widespread use of unproven therapies.
UNASSIGNED: This study established an expert consensus on 47 statements relating to the use of biologics in NFL athletes. In addition to providing clinical guidance for the use of biologics in NFL athletes, this study identified key areas for future focus including the development of athlete education materials.
摘要：
UASSIGNED：缺乏概述国家橄榄球联盟（NFL）运动员使用生物制剂的公开信息，指导生物治疗策略的数据有限。
UASSIGNED：在NFL团队医师之间就生物制剂的使用达成共识。
UNASSIGNED：共识声明。
UASSIGNED：由6名专家组成的工作组使用经过验证的Delphi方法召集了一个涉及NFL团队医生的共识过程。来自32支NFL球队以及NFL伦敦的医生被邀请参加。此迭代过程用于定义有关NFL运动员使用生物制剂的陈述。最近进行的一项关于专业运动员生物制剂的范围界定审查被用来为三轮调查中的第一轮提供信息，在7个标题下考虑的陈述：一般生物制品，对待NFL运动员的挑战，术语/命名法，自体血液制品,基于细胞的疗法，对NFL团队医生的指导，和NFL的生物学研究。除了评级协议，鼓励专家提出进一步的项目或修改。每次调查后，使用预定义的标准来细化项目列表。为了在最后一轮中达成共识，定义了先验，如果至少有75％的受访者同意且少于10％的受访者不同意，则将项目包括在最终信息集中。
UNASSIGNED：来自26支NFL球队和NFL伦敦的医师回应了最初的邀请，参加了Delphi过程；88.9％的参与团队医师完成了第一轮调查，第2轮的反应率为87.5%，第3轮的反应率为95.2%。经过三轮，47项声明达成共识。已达成共识，即富含血小板的血浆对髌腱病和早期骨关节炎的症状有积极影响，但对其他适应症没有影响。NFL团队医生一致认为，虽然细胞疗法有可能改善症状，将未经鉴定的制剂误称为“干细胞”，这导致了未经证实的疗法的广泛使用。
UNASSIGNED：这项研究就NFL运动员使用生物制剂的47项声明建立了专家共识。除了为NFL运动员使用生物制剂提供临床指导外，这项研究确定了未来重点关注的关键领域，包括运动员教育材料的开发。
UASSIGNED：在NFL团队医师之间就生物制剂的使用达成共识。
UNASSIGNED：共识声明。
UASSIGNED：由6名专家组成的工作组使用经过验证的Delphi方法召集了一个涉及NFL团队医生的共识过程。
UNASSIGNED：来自26支NFL球队和NFL伦敦的医师回应了最初的邀请，参加了Delphi过程；88.9％的参与团队医师完成了第一轮调查，
UNASSIGNED：这项研究就NFL运动员使用生物制剂的47项声明建立了专家共识。
